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Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant (mBRCA) have similar outcomes as non-carriers.
However, the impact of the type of gene (BRCA1 vs. BRCA2) and hormone receptor status (positive [HR+] vs. negative [HR−]) on
clinical behavior and outcomes of mBRCA BC remains largely unknown. This is an international, multicenter, hospital-based,
retrospective cohort study that included mBRCA patients diagnosed, between January 2000 and December 2012, with stage I–III
invasive early BC at age ≤40 years. From 30 centers worldwide, 1236 young mBRCA BC patients were included. Among 808 and 428
patients with mBRCA1 or mBRCA2, 191 (23.6%) and 356 (83.2%) had HR+tumors, respectively (P < 0.001). Median follow-up was 7.9
years. Second primary BC (P= 0.009) and non-BC malignancies (P= 0.02) were more frequent among mBRCA1 patients while
distant recurrences were less frequent (P= 0.02). Irrespective of hormone receptor status, mBRCA1 patients had worse disease-free
survival (DFS; adjusted HR= 0.76, 95% CI= 0.60–0.96), with no difference in distant recurrence-free interval (DRFI) and overall
survival (OS). Patients with HR+ disease had more frequent distant recurrences (P < 0.001) and less frequent second primary
malignancies (BC: P= 0.005; non-BC: P= 0.18). No differences in DFS and OS were observed according to hormone receptor status,
with a tendency for worse DRFI (adjusted HR= 1.39, 95% CI= 0.94–2.05) in patients with HR+ BC. Type of mBRCA gene and
hormone receptor status strongly impact BC clinical behavior and outcomes in mBRCA young patients. These results provide
important information for patients’ counseling on treatment, prevention, and surveillance strategies.
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INTRODUCTION
In women aged ≤40 years, breast cancer is the most common
malignancy and the first cause of cancer-related mortality1. Despite
the higher risk of developing triple-negative and HER2-positive
breast cancer, the majority of breast malignancies arising in young
patients are hormone receptor-positive tumors2. In young patients,
the prognosis for hormone receptor-positive breast cancers is worse
when compared to their older counterparts3.
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Other age-related issues should be considered in the manage-
ment of breast cancer in young women4. Among them, genetic
counseling and testing is key. Approximately 12% of cases arising
in women aged ≤40 years are related to germline pathogenic
variants in BRCA1 or BRCA25,6. Indeed, young age at diagnosis is a
criterion to refer patients to genetic counseling irrespective of
family history or other tumor biological features4. Identification of
a germline pathogenic variant in the BRCA genes plays a crucial
role in cancer prevention and treatment7,8. BRCA-related breast
cancers have distinct biological features, including a tendency for
hormone receptor-negativity in BRCA1 carriers and hormone
receptor positivity in BRCA2 carriers9–12.
Several studies have investigated the prognostic role of carrying
germline BRCA pathogenic variants13. Compared to women with
sporadic breast cancer, current evidence does not support
different outcomes in those with BRCA pathogenic variants13.
Similarly, no difference in survival outcomes between young
breast cancer patients with or without germline BRCA pathogenic
variants have been shown, except a trend for a survival advantage
in BRCA-mutated patients with triple-negative breast cancer
compared with non-carriers6. Nevertheless, besides the known
differences in clinicopathological features in breast cancer cases
associated with germline BRCA1 or BRCA2 pathogenic variants9–12,
there is a lack of evidence so far on whether the type of mutated
gene may also lead to potential differences in breast cancer
clinical behavior and outcomes. In addition, the prognostic value
of hormone receptor status in BRCA-related breast cancers
remains largely unknown. We addressed these important issues
in a large series of young breast cancer patients harboring
germline BRCA pathogenic variants.
RESULTS
Study cohort
Out of 1424 patients registered in the study from 30 centers
worldwide, 1236 young BRCA-mutated breast cancer patients
were eligible for inclusion in the present analysis (Supplementary
Fig. 1).
Among 808 and 428 patients with germline BRCA1 and BRCA2
pathogenic variants, 191 (23.6%) and 356 (83.2%) had hormone
receptor-positive tumors, respectively (P < 0.001).
Comparison between patients with germline BRCA1 and
BRCA2 pathogenic variants
Compared to patients in the BRCA2 cohort, those in the BRCA1
cohort were younger, more likely to have Israeli origin, had more
grade 3 tumors, less lobular histology, nodal involvement, and
HER2-positive disease (Table 1). Women in the BRCA1 cohort
received chemotherapy more frequently and, among those with
hormone receptor-positive disease, fewer patients received
adjuvant endocrine therapy (Table 1). Although patients in the
BRCA1 cohort underwent breast-conserving surgery more often,
no difference was observed in rates of risk-reducing mastectomy
or salpingo-oophorectomy between the BRCA1 and BRCA2
cohorts, respectively (Supplementary Table 1).
Supplementary Tables 2 and 3 report the comparison in
clinicopathological characteristics and risk-reducing surgery
between the BRCA1 and BRCA2 cohorts according to hormone
receptor status.
Median follow-up was 7.9 years (interquartile range 5.6–10.6
years), with no difference between the BRCA1 and BRCA2 cohorts
(P= 0.95). In terms of the first DFS event, second primary
malignancies (breast cancer: 17.0% vs. 12.2%, P= 0.009; non-
breast cancer: 4.3% vs. 1.9%, P= 0.02) were more frequent in the
BRCA1 cohort while distant recurrences were less frequent (10.4%
vs. 15.4%, P= 0.02) as compared to the BRCA2 cohort (Table 2).
When the pattern of the first DFS event was assessed between the
BRCA1 and BRCA2 cohorts according to hormone receptor status,
the only difference was a higher rate of second non-breast cancer
primary malignancies (5.2% vs. 1.4%, P= 0.005) in the BRCA1
cohort with hormone receptor-positive disease, being mostly
ovarian cancer (Supplementary Table 4).
Considering DFS events, a similar pattern of annual HRs was
observed between patients in the BRCA1 and BRCA2 cohorts
irrespective of hormone receptor status, with a higher risk for
those with BRCA1 pathogenic variants (Figs. 1a, 2a, and 3a).
Eight-year DFS was 62.8% and 65.9% in the BRCA1 and BRCA2
cohorts, respectively (adjusted HR= 0.76, 95% CI 0.60–0.96;
Fig. 1b). A tendency towards worse DFS in the BRCA1 cohort
was observed for both patients with hormone receptor-positive
(adjusted HR= 0.77, 95% CI 0.58–1.03; Fig. 2b) and negative
(adjusted HR= 0.73, 95% CI 0.48–1.13; Fig. 3b) breast cancer
(Pinteraction= 0.85; Supplementary Table 5).
Eight-year DRFI was 88.9% and 83.8% in the BRCA1 and BRCA2
cohorts, respectively (adjusted HR= 0.94, 95% CI 0.64–1.38; Fig.
1c). No significant difference in DRFI was observed for patients
with either hormone receptor-positive (adjusted HR= 0.94, 95% CI
0.60–1.48; Fig. 2c) or negative (adjusted HR= 0.92, 95% CI
0.43–1.95; Fig. 3c) breast cancer (Pinteraction= 0.95; Supplementary
Table 6).
Eight-year OS was 86.9% and 87.5% in the BRCA1 and BRCA2
cohorts, respectively (adjusted HR= 0.69, 95% CI 0.46–1.04; Fig.
1d). No significant difference in OS was observed for patients with
either hormone receptor-positive (adjusted HR= 0.64, 95% CI
0.39–1.05; Fig. 2d) or negative (adjusted HR= 0.80, 95% CI
0.40–1.56; Fig. 3d) breast cancer (Pinteraction= 0.62; Supplementary
Table 7).
Comparison between patients with hormone receptor-
positive and negative disease
Compared to patients with hormone receptor-negative disease,
those with hormone receptor-positive breast cancer were older,
had less grade 3 tumors, more often lobular histology, nodal
involvement, and HER2-positive disease (Supplementary Table 8).
Women with hormone receptor-positive breast cancer were less
likely to receive chemotherapy and underwent mastectomy more
often than those with hormone receptor-negative disease
(Supplementary Table 8). No differences were observed in rates
of risk-reducing mastectomy and salpingo-oophorectomy
between patients with hormone receptor-positive and negative
breast cancer, respectively (Supplementary Table 9).
In terms of first DFS event, patients with hormone receptor-
positive breast cancer had a higher incidence of distant (±loco-
regional) recurrences (16.1% vs. 9.0%, P < 0.001) and lower
incidence of second primary malignancies (breast cancer: 12.1%
vs. 17.9%, P= 0.005; non-breast cancer: 2.8% vs. 4.0%, P= 0.18)
compared to women with hormone receptor-negative disease
(Table 3). A similar pattern of annual HRs was observed between
patients with hormone receptor-positive and negative disease
until 5 years, beyond which a rapidly increasing trend for those
with hormone receptor-positive breast cancer was observed (Fig.
4a).
As reported in Supplementary Table 10, 8-year DFS was 62.9%
and 64.7% in patients with hormone receptor-positive and
negative disease, respectively (adjusted HR= 1.06, 95% CI
0.84–1.33; Fig. 4b). Eight-year DRFI was 83.4% and 90.1% in
patients with hormone receptor-positive and negative disease,
respectively (adjusted HR= 1.39, 95% CI 0.94–2.05; Fig. 4c). Eight-
year OS was 87.3% and 87.0% in patients with hormone receptor-
positive and negative disease, respectively (adjusted HR= 0.81,
95% CI 0.55–1.20; Fig. 4d).
Considering that the cut-off used for defining hormone receptor
positivity was not homogenous in all centers, the analyses
comparing between patients with hormone receptor-positive
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and negative disease were then repeated by including only
patients for whom the 1% cut-off for estrogen and/or progester-
one receptor expression in their tumor was used to define
hormone receptor status. Results were consistent with those
reported in the main analyses (Supplementary Tables 11–14 and
Supplementary Figs. 2–5).
DISCUSSION
This large unique dataset allowed an in-depth investigation of the
impact of the type of mutated gene (BRCA1 vs BRCA2) and
hormone receptor status on clinical behavior and outcomes of
BRCA-mutated breast cancer in young women. We observed that
patients with germline BRCA1 pathogenic variants had worse DFS
than those with BRCA2 pathogenic variants, mainly due to higher
rates of second primary malignancies (predominantly breast and
ovarian cancers) irrespective of hormone receptor status, with no
difference in DRFI and OS. Hormone receptor positivity was not
associated with favorable prognosis in BRCA-mutated breast
cancer, whatever the type of mutated gene, but rather it displayed
a tendency for worse DRFI and no difference in DFS and OS
compared to hormone receptor-negative disease. These data are
highly relevant for counseling young BRCA-mutated breast cancer
patients.
In terms of clinicopathological features, as shown in prior
studies9–12, the majority of breast cancer cases associated with
germline BRCA1 pathogenic variants were hormone receptor-
negative tumors (76%) while those arising in BRCA2-mutated
patients were hormone receptor-positive (83%). Overall, the majority
of tumors were high-grade (60–80%) and HER2-negative (90–95%),
both features being particularly relevant in the case of BRCA1
carriers9–12,14. In terms of clinicopathological characteristics in the
BRCA1 and BRCA2 cohorts according to hormone receptor status, the
features that remained differently distributed were country of origin
and tumor grade in patients with hormone receptor-positive disease
(more likely Israeli origin and high-grade tumors in the BRCA1
cohort) as well as age and HER2 status in those with hormone
Table 1. Patient, tumor and treatment characteristics.






Europe 611 (75.6) 611 (75.6)
North America 52 (6.4) 27 (6.3)
Latin America 34 (4.2) 13 (3.0)
Israel 111 (13.7) 28 (6.5)
Year at diagnosis 0.33
2000–2004 167 (20.7) 97 (22.7)
2005–2008 304 (37.6) 143 (33.4)
2009–2012 337 (41.7) 188 (43.9)
Age at diagnosis,
median (IQR) years
34 (30–37) 36 (33–38) <0.001
Age at diagnosis <0.001
≤30 years 206 (25.5) 64 (15.0)
31–35 years 281 (34.8) 143 (33.4)
36–40 years 321 (39.7) 221 (51.6)
Histology <0.001
Ductal carcinoma 645 (79.8) 346 (80.8)
Lobular carcinoma 10 (1.2) 29 (6.8)
Others 87 (10.8) 20 (4.7)
Missing 66 (8.2) 33 (7.7)
Tumor grade <0.001
G1 10 (1.2) 13 (3.0)
G2 110 (13.6) 140 (32.7)
G3 638 (79.0) 251 (58.6)
Missing 50 (6.2) 24 (5.6)
Tumor size 0.95
T1 (≤2 cm) 331 (41.0) 176 (41.1)
T2-T3-T4 (>2 cm) 459 (56.8) 247 (57.7)
Missing 18 (2.2) 5 (1.2)
Nodal status <0.001
N0 484 (59.9) 183 (42.8)
N1-N2-N3 311 (38.5) 240 (56.1)






191 (23.6) 356 (83.2)
ER and PR negative 617 (76.4) 72 (16.8)
HER2 status <0.001
HER2 negative 760 (94.1) 380 (88.8)
HER2 positive 28 (3.5) 40 (9.3)




428 (53.0) 158 (36.9)
Mastectomy 372 (46.0) 264 (61.7)
Missing 8 (1.0) 6 (1.4)
Use of chemotherapy <0.001
No 24 (3.0) 33 (7.7)
Yes 782 (96.8) 395 (92.3)






526 (67.3) 263 (66.6)
Anthracycline-based 196 (25.1) 110 (27.8)
Taxane-based 20 (2.6) 11 (2.8)
Others 19 (2.4) 6 (1.5)
Missing 21 (2.7) 5 (1.3)
Table 1 continued








No 28 (14.7) 15 (4.2)
Yes 160 (83.8) 339 (95.2)




Tamoxifen alone 71 (44.4) 145 (42.8)
Tamoxifen+ LHRHa 47 (29.4) 116 (34.2)
LHRHa alone 5 (3.1) 3 (0.9)
AI ± LHRHa 7 (4.4) 14 (4.1)
Tamoxifen and AI
?(±LHRHa)
29 (18.1) 58 (17.1)




60 (28.5 to 60) 60 (50 to 60) 0.02
IQR interquartile range, G tumor grade, T tumor size, N nodal status, ER
estrogen receptor, PR progesterone receptor, LHRHa luteinizing hormone-
releasing hormone agonist, AI aromatase inhibitors.
aCalculated after exclusion of missing values.
bCalculated among patients who received chemotherapy.
cCalculated among patients with hormone receptor-positive breast cancer.
dCalculated among patients with hormone receptor-positive breast cancer
who received endocrine therapy.
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receptor-negative tumors (younger age and more likely HER2-
negative status in the BRCA1 cohort).
Harboring a germline pathogenic variant in BRCA1 or BRCA2 was
not previously shown to have an apparent negative prognostic
impact in breast cancer13, neither in young patients6. Compared
with non-carriers, a tendency for better survival outcomes in BRCA
carriers with triple-negative breast cancer was shown6. In addition,
a reverse association of the prognostic value of hormone receptor
status was observed between breast cancer patients with or
without germline BRCA pathogenic variants6,15, particularly in the
case of BRCA2 pathogenic variants16–18. Nevertheless, within the
cohort of young BRCA-mutated breast cancer patients, the
prognostic implications of carrying a germline BRCA1 or BRCA2
pathogenic variant as well as potential differences according to
hormone receptor status remained largely undefined. Two main
findings with potential clinical implications were found in
our study.
Firstly, irrespective of hormone receptor status, the type of BRCA
gene does not appear to have prognostic value, with no observed
difference in DRFI and OS between BRCA1- and BRCA2-mutated
Table 2. Pattern of invasive disease-free survival events according to a type of BRCA-mutated gene.
BRCA1 cohort N (%) n= 808 BRCA2 cohort N (%) n= 428 P valuea
Follow-up, median (IQR) 7.9 (5.4 to 10.6) 7.9 (6.0 to 10.6) 0.95
No events 492 (60.9) 262 (61.2) 0.76
Loco-regional recurrence 54 (6.7) 36 (8.4) 0.35
Distant recurrence ± loco-regional recurrence 84 (10.4) 66 (15.4) 0.02
Second primary malignancy 35 (4.3) 8 (1.9) 0.02
Ovarian cancer 18 (2.2) 1 (0.2)
Other 7 (0.9) 4 (0.9)
Missing 10 (1.2) 3 (0.7)
Second primary breast cancer 137 (17.0) 52 (12.2) 0.009
Death without any disease-free survival event 6 (0.7) 4 (0.9) 0.79
IQR interquartile range.
aP-values for time-dependent events estimated by means of the Log-rank test.
Fig. 1 Comparison between patients with germline BRCA1 and BRCA2 pathogenic variants. a Epanechnikov Kernel-Smoothed annual
hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall survival.
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patients. This is reassuring evidence for counseling young BRCA-
mutated breast cancer patients. Nevertheless, BRCA1 carriers
showed worse DFS, mostly due to higher rates of second primary
malignancies (predominantly breast and ovarian cancers) as
compared to BRCA2-mutated patients. This result reflects the
different and age-dependent risk of cancer development asso-
ciated with the two genes: the breast cancer peak of incidence
occurs earlier and ovarian cancer risk is higher in BRCA1 carriers as
compared to those with BRCA2 pathogenic variants19,20. Young
age at cancer diagnosis further increases the risk of second
primary breast and ovarian malignancies19,21–23. Therefore, these
findings highlight the key role of BRCA genetic testing in this
patient population and calls for awareness of the high risk of
secondary malignancies and the option of considering risk-
reducing surgeries when a pathogenic variant is identified,
particularly in BRCA1 carriers24,25. In addition, these results
pinpoint the need to consider age-specific risk estimates when
offering these procedures during patients’ counseling23.
Secondly, irrespective of the type of BRCA-mutated gene,
hormone receptor positivity has no favorable prognostic value in
this setting. While no difference in DFS and OS was observed,
patients with hormone receptor-positive breast cancer showed a
higher risk of distant relapses and a trend for worse DRFI as
compared to those with hormone receptor-negative disease.
There are several potential explanations for this lack of prognostic
advantage in young BRCA-mutated patients with hormone
receptor-positive breast cancer. Estrogen signaling was shown to
promote tumor initiation and progression in BRCA-deficient
cells26,27. Biological differences were reported between hormone
receptor-positive breast cancers arising in patients with or without
germline BRCA pathogenic variants28,29. When tested with
OncotypeDx, a larger proportion of BRCA-mutated patients were
found to have high recurrence scores, and low recurrence score
was not necessarily associated with low risk of recurrence30–32.
Taking into account that our study included only patients ≤40
years at diagnosis, these considerations may be further amplified
due to the additional effect of young age on the biology of
hormone-receptor-positive breast cancers2,3. Finally, it should be
highlighted that BRCA-related tumors are known to have high
chemosensitivity11,17,33, particularly in the case of hormone
receptor-negative disease34,35. In our study, more than 90% of
the patients received chemotherapy. However, ~8% of patients
with hormone receptor-positive disease did not receive adjuvant
endocrine therapy, with significantly higher numbers of non-
recipients among BRCA1 carriers. Although the reasons for lack of
endocrine therapy administration were not collected, special
attention should be paid in this regard when counseling BRCA-
mutated patients with hormone receptor-positive disease. Our
findings provide indirect evidence to potentially consider BRCA-
mutated patients with hormone receptor-positive disease as a
high-risk population36. Therefore, ovarian function suppression37
and extended adjuvant endocrine therapy38 may be considered
relevant options in this setting. In light of the increased ovarian
cancer risk, risk-reducing salpingo-oophorectomy might be
considered as the primary strategy for ovarian function
Fig. 2 Comparison between patients with germline BRCA1 and BRCA2 pathogenic variants and hormone receptor-positive disease. a
Epanechnikov Kernel-Smoothed annual hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall
survival.
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suppression in eligible patients who have completed their family
planning.
The findings of this study should be considered in the context
of its limitations. This is a retrospective cohort study conducted
over a relatively long period of time. Assessment of BRCA and
hormone receptor status as well as patient management were
conducted according to diagnostic and treatment procedures
available at that time in the respective country and center. Median
follow-up was shorter than 10 years. Nevertheless, several unique
features of this study should also be highlighted. This is a
multicenter study, not restricted to a single continent, that
included a large sample size despite focusing on a special and
rare patient population (i.e., young breast cancer patients with
germline BRCA pathogenic variants). The numbers of included
patients and registered events made possible the acquisition of
Fig. 3 Comparison between patients with germline BRCA1 and BRCA2 pathogenic variants and hormone receptor-negative disease. a
Epanechnikov Kernel-Smoothed annual hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall
survival.
Table 3. Pattern of invasive disease-free survival events according to hormone receptor status.
Hormone receptor-positive N (%) n= 547 Hormone receptor-negative N (%) n= 689 P valuea
Follow-up, median (IQR) 7.8 (5.8–10.6) 7.9 (5.5–10.6) 1.00
No events 329 (60.1) 425 (61.7) 0.91
Loco-regional recurrence 45 (8.2) 45 (6.5) 0.28
Distant recurrence +/− loco-regional recurrence 88 (16.1) 62 (9.0) <0.001
Second primary malignancy 15 (2.8) 28 (4.0) 0.18
Ovarian cancer 7 (1.3) 12 (1.7)
Other 6 (1.1) 5 (0.7)
Missing 2 (0.4) 11 (1.6)
Second primary breast cancer 66 (12.1) 123 (17.9) 0.005
Death without any disease-free survival event 4 (0.7) 6 (0.9) 0.75
IQR interquartile range.
aP-values for time-dependent events estimated by means of the Log-rank test.
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reliable results on these important unmet and clinically highly
relevant issues.
In conclusion, type of BRCA-mutated gene and hormone
receptor status strongly impact the clinical behavior and out-
comes of breast cancer in young patients with germline BRCA
pathogenic variants. Young patients with germline BRCA1
pathogenic variants had worse DFS than those with germline
BRCA2 pathogenic variants mostly due to higher rates of second
primary malignancies irrespective of hormone receptor status. On
the other hand, unlike breast cancers arising in non-BRCA carriers,
hormone receptor status had no prognostic value in young BRCA-
mutated patients, and even a tendency of worse DRFI in women
with hormone receptor-positive disease was observed. These
results provide important information for counseling young BRCA-
mutated breast cancer patients regarding treatment, prevention
and surveillance strategies.
METHODS
Study design and participants
Details of this study were previously reported39. Briefly, this was an
international, multicenter, hospital-based, retrospective cohort study that
included women diagnosed at age ≤40 years with invasive early breast
cancer (stage I–III) between January 2000 and December 2012. All included
patients had a known germline BRCA1 or BRCA2 pathogenic variant.
Healthy carriers as well as women with BRCA variants of uncertain
significance, other malignancies (including ovarian cancer) without a prior
diagnosis of invasive breast cancer, in situ or stage IV de novo breast
cancer, or lack of information on follow-up were not eligible for inclusion.
For the purpose of the present analysis, patients harboring pathogenic
variants in both BRCA1 and BRCA2 as well as those with unknown hormone
receptor status were also excluded.
Datasets from countries with more than one participating center were
crosschecked to exclude potential duplicated cases.
Procedures
Data on tumor and patient characteristics, treatment, BRCA pathogenic
variants, and survival outcomes were collected for all eligible patients.
The type of mutated gene was the criteria used to distinguish between
two cohorts of patients: women with BRCA1 (BRCA1 cohort) and those with
BRCA2 (BRCA2 cohort) pathogenic variants.
BRCA pathogenic variants and hormone receptor status were assessed
locally at each participating center. Hormone receptor positivity was
defined by the expression of estrogen and/or progesterone receptors in
≥1% of invasive tumor cells (≥10% in French participating centers)
assessed by immunostaining.
The Institut Jules Bordet (Brussels, Belgium) coordinated the study and
acted as the central ethics committee. Ethics approval by the Institutional
Review Boards of participating centers and patients’ written informed
consent were obtained before inclusion whenever requested by local
regulations.
The STrengthening the Reporting of OBservational studies in Epidemiol-
ogy (STROBE) statement was followed for study reporting40.
Outcomes
The current analysis aimed to investigate the impact of the type of
mutated gene (BRCA1 vs. BRCA2) and hormone receptor status on clinical
Fig. 4 Comparison between patients with hormone receptor-positive and negative disease. a Epanechnikov Kernel-Smoothed annual
hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall survival. HR+ hormone receptor-positive; HR
− hormone receptor-negative.
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behavior and outcomes of young breast cancer patients with germline
BRCA pathogenic variants.
Clinicopathological characteristics, pattern, and risk over time of disease-
free survival (DFS) events, as well as prognosis (in terms of DFS, distant
recurrence-free interval [DRFI], and overall survival [OS]) were compared
between the BRCA1 and BRCA2 cohorts. The same analyses comparing the
BRCA1 and BRCA2 cohorts were then performed separately in patients with
hormone receptor-positive and negative disease.
To specifically assess the effect of hormone receptor status, clinico-
pathological characteristics, pattern, and risk over time of DFS events, as
well as prognosis (in terms of DFS, DRFI, and OS) were compared between
patients with hormone receptor-positive and negative disease irrespective
of the type of mutated gene.
Statistical analysis
Descriptive analyses were used to assess clinicopathological characteristics
as well as the pattern of DFS events.
To assess the risk of developing DFS events over time, the Epanechnikov
Kernel-Smoothed annual hazards of recurrence were calculated.
DFS was defined as the time from diagnosis until the first appearance of
one of the following invasive events: loco-regional recurrence, distant
metastases, new contralateral or ipsilateral breast cancer, second primary
malignancy, or death from any cause. DRFI was calculated as the time from
diagnosis until the first occurrence of invasive breast cancer recurrence at a
distant site. OS was defined as the time from diagnosis until death from
any cause.
Observation times of patients that did not experience an event were
censored on the date of their last contact. Kaplan–Meier plots were used to
present results with a follow-up time of up to 10 years. Cox proportional
hazard model was applied to estimate the hazard ratios (HRs) over the
whole follow-up period, adjusting for the concomitant effect of selected
confounders. Multivariate models for all survival analyses included nodal
status, grade, HER2, type of breast surgery, chemotherapy use, age, year of
diagnosis, and country.
Homogeneity tests on the HRs were performed in all survival analyses
using the likelihood ratio test to assess whether there was evidence of an
interaction between the type of gene and hormone receptor status.
All statistical analyses were two-sided; P values < 0.05 were considered
as statistically significant. Statistical analyses were performed by MC and
MB using Stata 13.1 (StataCorp. 2013. Stata Statistical Software: Release 13.
College Station, TX: StataCorp LP).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data generated and analysed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.1350742241. The data are stored in
the following four Excel spreadsheets: ‘Patient survival data.xlsx’, ‘Patient baseline,
tumor and treatment data.xlsx’, ‘Patient risk-reducing surgery data.xlsx’, ‘Patient
eligibility criteria and survival data.xlsx’. These data are not publicly available for the
following reason: data contain information that could compromise research
participant privacy. However, the data can be made available upon reasonable
request to the corresponding author. A list of which data file underlies which figure,
table, and supplementary table in the related manuscript is provided in the file
‘Lambertini et al. underlying data lookup.csv’, included as part of the metadata
record41. The dataset analysed during this study is described with more details in the
following manuscript: https://doi.org/10.1200/JCO.19.0239939.
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